To better understand how USP35 modulates the anti-tumor ability of oncolytic virotherapy, CD4+/CD8+ T cell and macrophage type were analyzed by flow cytometric assays (Supplementary Fig. 5A, B, Supplementary Fig. 6A, B). This evidence concerns the gene CD8A and neoplasm.